Speakers will highlight ways to Streamline Medical Affairs Workflows using QUOSA and Article Galaxy
Los Angeles, Calif., May 16, 2014 – Reprints Desk, Inc., a wholly-owned subsidiary of Research Solutions, Inc. (RSSS), today announced two webinars are scheduled on May 28, 2014 to highlight how QUOSA and Article Galaxy can be used together to efficiently acquire, manage and share relevant scientific literature for Medical Liaisons, Medical Communications, and other groups within Medical Affairs.
Online registration for “Streamlining Medical Affairs Workflows” is free and available online at http://www.elsevier.com/online-tools/quosa/news/webinar-streamlining-medical-affairs-workflows.
The webinars will explore how corporate libraries, information centers and Medical Affairs staff can improve the tasks they normally perform including:
- Responding quickly to inquiries from HCPs and KOLs
- Enabling mobile access to content
- Ordering & distributing documents legally to KOLs
- Tracking spending to comply with Sunshine Act regulation
- Saving money by preventing duplicate article orders
- Optimizing spending through the use of lowest cost literature acquisition filters
The QUOSA solution is a centralized repository of scientific literature that enables life sciences institutions to meet regulatory reporting requirements, address medical inquiries and maintain current awareness in relation to topics or authors. It is used by a broad array of groups such as pharmacovigilance and medical affairs personnel in pharma, biotech and medical device companies. QUOSA is part of Elsevier’s Life Science Solutions, a portfolio of interoperable, domain-specific, decision support tools which span the discovery and development workflow; including Pathway Studio™, Reaxys ®, Reaxys ® Medicinal Chemistry, ScienceDirect, Scopus, PharmaPendium® and Embase®.
Corporations, academic institutions, and government organizations around the world rely on Reprints Desk and its Article Galaxy online platform for single article document delivery research retrieval for obtaining copyrighted journal content that complies with applicable copyright laws when subscriptions do not exist. Since 2008 Reprints Desk has held lone honors as the top-rated document supplier in the document delivery market research survey conducted by information analyst and advisory firm Outsell, Inc.
For more information about Reprints Desk, visit www.reprintsdesk.com. For more information about QUOSA, visit www.quosa.com.
About Reprints Desk®
Reprints Desk improves how journal articles and clinical reprints are accessed, procured, and used in a copyright compliant manner in evidence-based promotions, medical affairs, and scientific, technical, and medical (STM) research. Organizations fueled by intellectual property (IP) choose Reprints Desk because of its collaborative business approach, efficient article supply system and services, and commitment to quality post-sales support. Reprints Desk has ranked #1 in the every Document Delivery Vendor Scorecard from industry analyst and advisory firm Outsell Inc. since 2008. Reprints Desk is a wholly owned subsidiary of Research Solutions, Inc. (RSSS).
Certain matters discussed in this press release may be forward-looking statements. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in obtaining new customers; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; the Company's success in integrating acquired entities and assets, and all the risks and related information described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"), including the financial statements and related information contained in the Company's Annual Report on Form 10-K and interim Quarterly Reports on Form 10-Q. Examples of forward-looking statements in this release include statements related the Company's products. The Company assumes no obligation to update the cautionary information in this release.